Pharmacological effects Pharmacokinetics Clinical indications and usage
ChemicalBook > CAS DataBase List > Posaconazole


Pharmacological effects Pharmacokinetics Clinical indications and usage
Posaconazole Structure
  • CAS No.171228-49-2
  • Chemical Name:Posaconazole
  • CBNumber:CB9946972
  • Molecular Formula:C37H42F2N8O4
  • Formula Weight:700.78
  • MOL File:171228-49-2.mol
Posaconazole Property
  • Melting point: :170-1720C
  • Boiling point: :850.7±75.0 °C(Predicted)
  • Density  :1.36±0.1 g/cm3(Predicted)
  • Flash point: :9℃
  • storage temp.  :-20°C Freezer
  • pka :14.72±0.20(Predicted)
  • form  :powder
  • color  :white to beige
  • optical activity :[α]/D -24 to -32°, c = 1.0 in chloroform-d
  • Merck  :14,7602
  • CAS DataBase Reference :171228-49-2(CAS DataBase Reference)
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H225-H301+H311+H331-H370
  • Precautionary statements P210-P260-P280-P301+P310-P311
Posaconazole Price More Price(9)
  • Brand: Sigma-Aldrich
  • Product number: 32103
  • Product name : Posaconazole
  • Purity: VETRANAL
  • Packaging: 25mg
  • Price: $105
  • Updated: 2020/08/18
  • Buy: Buy
  • Brand: Sigma-Aldrich
  • Product number: P-103
  • Product name : Posaconazole solution
  • Purity: 
  • Packaging: 103-1ml
  • Price: $108
  • Updated: 2020/08/18
  • Buy: Buy
  • Brand: TCI Chemical
  • Product number: P2477
  • Product name : Posaconazole
  • Purity: >98.0%(HPLC)
  • Packaging: 10mg
  • Price: $49
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: TCI Chemical
  • Product number: P2477
  • Product name : Posaconazole
  • Purity: >98.0%(HPLC)
  • Packaging: 50mg
  • Price: $146
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 14737
  • Product name : Posaconazole
  • Purity: ≥95%
  • Packaging: 1mg
  • Price: $48
  • Updated: 2020/06/24
  • Buy: Buy

Posaconazole Chemical Properties,Usage,Production

  • Pharmacological effects Posaconazole (posaconazole) is derived from itraconazole. It is currently subject to III phase clinical trials. Its pharmacological effects are similar with azoles, but compared with itraconazole, it has a stronger inhibitory effect on the C14 demethylation of steroid, especially for Aspergillus.
  • Pharmacokinetics Studies on dosage and dosage protocol have shown that the rate of absorption and elimination rate is in line with the single-compartment model. There are significant differences on the relative bioavailability of different doses of oral suspension. It can be taken separately (every 12 hours or every 6 hours) which can significantly improve the bioavailability with the protein binding rate of 98% to 99%. With respect to tablets, the bioavailability of suspensions increase and food can significantly improve the speed and extent of absorption of drug absorption. An investigation of renal dysfunction on the pharmacokinetics of the drug study results has showed that the drug can’t be removed by hemodialysis without being affected by hemodialysis. Single-dose study has showed that patients with varying degrees of chronic kidney disease have no necessity for dosage adjustment. The Half-life of this is about 25 hours which can be primarily metabolized by the liver.
  • Clinical indications and usage It can be clinically used for the treatment of aspergillosis, zygnmycosis, and fusariumsis and can also be used for infection caused by part of fluconazole-resistant Candida genus. Studies have shown that posaconazole can widely and effectively applied to the treatment of phaeohyphomycosis and improve the infection survival rate of dermatitidis infection in a dose-dependent manner. The drug, as second-line drugs, has an effective rate of 44% to 78% against the invasive aspergillosis which is resistant to amphotericin B and itraconazole. It also has an effective rate of 71% against the zygomycete fungi. The drug is an oral suspension with the recommended dose of 200mg and 4 times per day with meals and taken orally for 7 to 10 days. This dose can also be maintained or changed to 400mg with oral administration of 2 times per day. The steady-state plasma concentration can reach within 7 to 10 days.
    The above information is edited by the Chemicalbook of Dai Xiongfeng.
  • Description Posaconazole, launched in the UK, is the newest member of the azole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itraconazole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posaconazole has an expanded spectrum of activity over other members of the azole antifungals. In addition to potent activity against refractory cases of aspergillosis and fluconazole-resistant Candida, it demonstrates activity against Zygomycetes.
  • Chemical Properties White Solid
  • Originator Schering-Plough (US)
  • Uses Orally active triazole antifungal.
  • Uses Posaconazole is a sterol C14ɑ demethylase inhibitor with an IC50 of 0.25 nM
  • Definition ChEBI: An N-arylpiperazine that consists of piperazine carrying two 4-substituted phenyl groups at positions 1 and 4. A triazole antifungal drug.
  • brand name Noxafil
  • Antimicrobial activity The spectrum includes dimorphic fungi (Blast. dermatitidis, Coccidioides spp., Hist. capsulatum, Pen. marneffei, and Spor. schenckii), molds (Aspergillus spp., Mucor spp., Rhizomucor spp. and Rhizopus spp.), some dematiaceous fungi and yeasts (Candida spp. and Cryptococcus spp.).
  • General Description Technetium (99mTc) exametazime is a mixture of unstablelipophilic enantiomers that rapidly cross the blood-brain barrierand is trapped in the tissues. The proposed trapping mechanismfor localization includes reduction by glutathione. Asimilar diffusion and trapping process occurs with autologouslymphocytes in vitro.
    Exametazime is also known as hexamethylpropyleneamineoxime or HMPAO. The radiolabeled complex is indicated for cerebral perfusion in stroke, but is most commonlyused for the radiolabeling of autologous leukocytesas an adjunct in the localization of intra-abdominal infectionand inflammatory bowel disease.
    Each kit includes several components: (a) reaction vialscontaining a mixture of exametazime, stannous chloride,and sodium chloride; (b) vials of 1% methylene blue; (c)vials of phosphate buffer in 0.9% NaCl; and (d) 0.45-μm syringefilters. Product preparation depends on the intendeduse.
  • Pharmaceutical Applications A synthetic triazole available for oral administration.
  • Pharmacokinetics Cmax 200 mg oral: 0.5 mg/L after 4 h
    Plasma half-life: 35 h
    Volume of distribution: 1774 L
    Plasma protein binding: >98%
    Oral absorption is slow. Absorption from the gastrointestinal tract is improved if the drug is given with a high-fat meal. Blood concentrations increase in proportion to dosage up to 800 mg.
    It is extensively distributed into body tissues.
    Metabolism and excretion
    It is not as extensively metabolized by the hepatic cytochrome P450 system as other triazole antifungals. More than 70% of an administered dose is eliminated in the feces, predominantly as unchanged drug. The remainder is excreted as glucuronidated derivatives in the urine. Posaconazole is a substrate for intestinal P-glycoprotein,an adenosine triphosphate-dependent plasma membrane transporter responsible for drug efflux from cells. Multiple peaks in blood concentrations have been observed, suggesting that effluxed drug is reabsorbed into the systemic circulation.
  • Clinical Use Invasive aspergillosis
    Fusarium infection
    Chromoblastomycosis and mycetoma
    Oropharyngeal candidosis
    Prophylaxis of invasive fungal infections in patients at serious risk
    With the exception of oropharyngeal candidosis and prophylaxis, use is presently restricted to patients with disease that is refractory to other antifungal drugs, or who are intolerant to them.
  • Side effects It is generally well tolerated even for long periods. Unwanted effects include gastrointestinal discomfort and mild to moderate, transient abnormalities of liver enzymes. Rare side effects include cholestasis and hepatic failure.
Posaconazole Preparation Products And Raw materials
Raw materials
Preparation Products
  • Supplier:
  • Tel:13812269233
  • Fax:0510-83591909
  • Country:CHINA
  • ProdList:168
  • Advantage:58
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Country:CHINA
  • ProdList:22623
  • Advantage:55
  • Supplier:
    Hangzhou FandaChem Co.,Ltd.
  • Tel:0086 158 5814 5714 (Mobile
  • Fax:+86-571-56059825
  • Country:CHINA
  • ProdList:3292
  • Advantage:55
  • Supplier:
    Shanghai Yingrui Biopharma Co., Ltd.
  • Tel:+86-21-33585366
  • Fax:+86-21-34979012
  • Country:CHINA
  • ProdList:739
  • Advantage:60
  • Supplier:
  • Tel:+86 21 5161 9050/ 5187 7795
  • Fax:+86 21 5161 9052/ 5187 7796
  • Country:CHINA
  • ProdList:24948
  • Advantage:60
171228-49-2, PosaconazoleRelated Search:
  • 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one
  • 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-Triazol-1-yl)methyl)-5-(2,4-difluorobenzyl)tetrahydrofuran-3
  • Posaconazole(Form Ⅲ)
  • Posaconazole
  • 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol
  • Noxafil
  • Sch 56592
  • Posaconazole for research
  • 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
  • Aids058495
  • Aids-058495
  • 4-[4-[4-[4-[[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
  • POSACONAZOLE whatsapp
  • EOS-60773
  • Posaconazole and intermediates
  • posaconazote
  • Posaconazole(Form Ⅰ)
  • Posacozole
  • CS-140
  • Posaconazole - SCH 56592 | Noxafil
  • Pcz
  • Pos
  • Posconazole
  • 4-(4-(4-(4-(((3R,5R)-5-(3,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)tetrahydrofuran-3-yl)Methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-1H-1,2,4-triazol-5(4H)-one
  • 4-{4-[4-(4-{[(3S,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylMethyl)oxolan-3-yl]Methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one
  • 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-Triazol-1-yl)Methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)Methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-1H-1,2,4-triazol-5(4H)-one
  • D-threo-Pentitol,2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]Methyl]-1-(1H-1,2,4-triazol-1-yl)-
  • Pasaconazole
  • 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one
  • Posaconazole 4-[4-[4-[4-[[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
  • Posaconazole solution
  • Posaconazole Amorphous
  • Posaconazole, >=99%
  • Technetium (99mTc) exametazime
  • 171228-49-2
  • C37H42F2N8O4
  • API
  • Noxafil
  • Inhibitors
  • Chiral Reagents
  • Intermediates & Fine Chemicals
  • Pharmaceuticals